Free Consultation Request
* denotes required fields
I agree to the KTMC disclaimer
I would like to receive new case alerts by email

Investigation of Potential Action on Behalf of Insulet Corporation (PODD)

Kessler Topaz Meltzer & Check, LLP is investigating a potential shareholder action on behalf of current shareholders of Insulet Corporation (“Insulet”).

About Insulet

Insulet is a medical device company that develops, manufactures and markets the OmniPod Insulin Management System (the “OmniPod System”), a proprietary insulin infusion system.

Alleged Wrongful Conduct

Kessler Topaz Meltzer & Check, LLP is investigating potential breaches of fiduciary duties by members of Insulet’s Board of Directors in connection with statements made to shareholders about the OmniPod System.

On April 30, 2015, Insulet announced disappointing quarterly financial results as a result of delayed shipments of its infusion system, the OmniPod Eros ("OmniPod").  Following this news, shares of the Company’s stock declined nearly 10%.  Subsequently, the Company reported that it had received a Warning Letter from the FDA concerning the safety of certain OmniPod pods manufactured and shipped between mid-2013 and the first half of 2014.

If you currently own shares of Insulet Corporation (NASDAQ: PODD) and would like to learn more about our investigation, please fill out our online form or contact us today at (888) 299–7706 or info@ktmc.com.